Zydus Lifesciences Limited (ZYDUSLIFE) — Financial Results | 5 February 2025(5 announcements)

Zydus Lifesciences reported consolidated revenue of ₹169,025 crores for the nine-month period ended December 31, 2024, up 32% YoY, driven by pharmaceutical growth. Net profit reached ₹1,404 crores, reflecting strong operational performance despite one-time losses from asset disposals. The Board approved results on February 5, 2025, with a limited review confirming no material misstatements. Share buybacks completed in March 2024 reduced paid-up capital to ₹1,006 lakhs. Discontinued operations contributed minor current-period amounts, while strategic acquisitions in biotech underscore long-term expansion. Investor focus remains on sustainable growth in high-margin therapeutic segments.

Zydus Lifesciences reported Q3 FY25 revenue of ₹52,691 crores, up 17% YoY, and net profit of ₹10,235 crores, up 30% YoY, driven by strong US formulation growth and new product launches. EBITDA rose 26% to ₹13,876 crores with margin expansion to 26.3%. The company highlighted pipeline progress, including USFDA approvals and a strategic acquisition in consumer snacks, while maintaining its double-digit growth target for FY25.

Zydus Lifesciences reported consolidated revenue of ₹108,187 crores for the nine months ended December 31, 2024, up sharply from ₹25,159 crores in the prior quarter, with net profit reaching ₹29,612 crores. The growth reflects strong performance in pharmaceuticals and recent strategic acquisitions, including a 50% stake in Sterling Biotech. The company completed a share buyback worth ₹7,250 crores and finalized the acquisition of Naturell (India) for ₹3,690 crores upfront. No defaults, related party transactions, or audit qualifications were noted. The financials underscore robust operational momentum and capital efficiency.

Zydus Lifesciences reported a 69.9% YoY revenue increase to ₹87.22 crores for Q3 FY2025, driven by strong domestic sales growth of 32% and international expansion of 15%, while net profit rose 28% to ₹12.45 crores on improved margins and cost optimization.

Zydus Lifesciences reported a 17% YoY revenue increase to ₹52,691 million for Q3 FY25, driven by strong performance across all segments. EBITDA margin expanded to 26.3% (+180 bps YoY), with net profit rising 29.6% to ₹10,235 million. The company highlighted robust volume growth in Consumer Wellness and chronic outperformance in India formulations, alongside strategic US FDA approvals and pipeline progress in biotech. Forward-looking statements indicate continued investment in R&D and expansion in high-growth therapeutic areas.